Burkly Linda 4
4 · Editas Medicine, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Editas Medicine (EDIT) EVP/CSO Linda Burkly Sells 731 Shares
What Happened Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine (EDIT), sold 731 shares on June 3, 2026. The filing reports a weighted average price of $2.70 per share for a total value of approximately $1,975. This was a sale (not a purchase) and is presented as a routine disposition to meet tax obligations rather than an active, discretionary trade.
Key Details
- Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (timely filing).
- Reported price/total: $2.70 weighted average; total proceeds ≈ $1,975.
- Execution detail: Trades were executed in multiple transactions at prices ranging $2.7010–$2.7050 (footnote F2); the filing offers to provide full trade-level details on request.
- Reason/footnote: Sale effected under a durable automatic sales instruction plan adopted July 3, 2023, to cover tax withholding for restricted stock units that vested June 2, 2026; the sale was not a discretionary trade by the reporting person (footnote F1).
- Shares owned after transaction: Not disclosed in the provided filing.
Context This was a tax-withholding sale tied to RSU vesting, which is common and typically not interpreted as a signal about the insider’s view of the company. Sales under automatic plans or for tax withholding are routine; purchases would be more indicative of a positive insider signal.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-03$2.70/sh−731$1,975→ 67,297 total
Footnotes (2)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7050. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.